(3-trifluoromethyl-4-nitro)benzamide | 22227-56-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-trifluoromethyl-4-nitro)benzamide
• 英文别名: 4-nitro-3-(trifluoromethyl)benzamide
• CAS: 22227-56-1
• 化学式: C₈H₅F₃N₂O₃
• 分子量: 234.135
• InChiKey: DUAQUZMDHPPFCZ-UHFFFAOYSA-N

物化性质

• 熔点：
  136-138 °C
• 沸点：
  318.8±42.0 °C(Predicted)
• 密度：
  1.525±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  88.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Pyrrole Derivatives As Pharmaceutical Agents
  申请人：Canne Bannen Lynne

  公开号：US20080234270A1

  公开（公告）日：2008-09-25

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  提供了用于调节受体活性的化合物、组合物和方法。特别提供了用于调节受体活性的化合物和组合物，以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱的症状的方法。
• [EN] ONE-STEP 18F LABELING OF BIOLOGICAL SUBSTRATES AND USES OF 18F LABELED BIOLOGICAL SUBSTRATES<br/>[FR] MARQUAGE AU 18F EN UNE SEULE ÉTAPE DE SUBSTRATS BIOLOGIQUES ET UTILISATIONS DESDITS SUBSTRATS BIOLOGIQUES MARQUÉS AU 18F
  申请人：US HEALTH

  公开号：WO2012094334A1

  公开（公告）日：2012-07-12

  Disclosed is a rapid one-step 18F radiolabeling method for biological substrates that contain a specific arene group activated for nucleophilic aromatic substitution with 18F. The method involves reacting a biological substrate having at least one 4-nitro-3-trifluorobenzamide moiety covalently bonded thereto with a 18F anion in the presence of a cryptand. The method of the present invention has one or more advantages: significantly shortens reaction and overall synthesis time; requires low amount of precursor; and provides acceptable yields of high specific activity product. Also disclosed are methods of identifying a cell or population of cells expressing a protein or peptide of interest and methods for diagnosing a disease in a subject. Further disclosed are 18F labeled compounds of formula (I): wherein X, n, R1, R2, and R3 are as described herein.

  本文揭示了一种用于含有特定芳烃基团的生物底物的快速一步18F放射性标记方法，该基团被激活用于与18F进行亲核芳香取代。该方法涉及在存在cryptand的情况下，将至少有一个4-硝基-3-三氟苯甲酰基团共价键合到生物底物上的生物底物与18F阴离子反应。本发明的方法具有一个或多个优点：显著缩短了反应和整体合成时间；需要较少的前体量；并提供了高比活性产物的可接受产量。还揭示了用于识别表达感兴趣蛋白质或肽的细胞或细胞群的方法，以及用于诊断受试者疾病的方法。进一步揭示了化合物的18F标记的公式（I）：其中X，n，R1，R2和R3如本文所述。
• [EN] THIAZOLINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)<br/>[FR] DERIVES DE THIAZOLINE SERVANT DE MODULATEURS DE RECEPTEUR DES ANDROGENES SELECTIFS (SARMS)
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004113309A1

  公开（公告）日：2004-12-29

  The present invention is directed to novel thiazoline derivatives of the general fomula (I); wherein all variables are as herein defined, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及一种新型噻唑啉衍生物，其一般式为(I)；其中所有变量如本文所定义，包含它们的药物组合物，并且它们在治疗由雄激素受体调节的疾病和症状中的用途。
• NOVEL IMIDAZOLOPYRAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
  申请人：Zhang Xuqing

  公开号：US20070197616A1

  公开（公告）日：2007-08-23

  The present invention is directed to novel imidazolopyrazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及新型咪唑吡唑酮衍生物，含有它们的药物组合物以及它们在治疗受雄激素受体调节的疾病和症状中的用途。
• Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
  申请人：——

  公开号：US20030181728A1

  公开（公告）日：2003-09-25

  Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  熔合环化合物，使用这种化合物治疗与核激素受体相关的疾病，如癌症和免疫紊乱的方法，以及包含这种化合物的制药组合物。